Taxane-induced Peripheral Sensorial Neuropathy in Cancer Patients is Associated with Duration of Diabetes Mellitus: a Single-center Retrospective Study

Overview

Journal Support Care Cancer

Specialties Critical Care
Oncology

Date 2015 Aug 18

PMID 26279147

Citations 21

Authors

Tulay Kus

Gokmen Aktas

Mehmet Emin Kalender

Alper Sevinc

Seval Kul

Ali Suner

Esra Ulker

Celaletdin Camci

Affiliations

Soon will be listed here.

Abstract

Purpose: The purpose of this study was to determine whether the presence of diabetes mellitus (DM) influences the incidence and severity of peripheral sensory neuropathy (PSN) in patients using taxane therapy.

Methods: A retrospective single-center analysis was conducted: Patients with PSN at baseline were excluded. The incidence of PSN was evaluated retrospectively in patient subgroups who received taxane arm and taxane-plus-platinum-agents combination arm with or without known DM at baseline.

Results: Three hundred seventy-four patients were enrolled in this study, 81 (21.6%) of patients had DM at baseline. The incidence of grade 1 PSN (non-DM/DM) in patients receiving taxane-based chemotherapy was 33.4/25.9% and more than grade 2 PSN (non-DM/DM) was 15/34.6%. The rate of neuropathy of non-diabetic patients was 48.8%, while the rate of diabetic patients was 52.8 and 75% in DM duration below 5 years and above 5 years group, respectively.

Conclusions: This retrospective analysis indicates that taxane-based therapy in DM patients whose disease duration is above 5 years appears to affect the incidence and severity of PSN without known baseline neuropathy. The probability of PSN with taxane-based therapy was similar in DM duration below 5 years and non-DM patients.

Citing Articles

Insulin resistance and cancer: molecular links and clinical perspectives.

Caturano A, Erul E, Nilo R, Nilo D, Russo V, Rinaldi L Mol Cell Biochem. 2025; .

PMID: 40089612 DOI: 10.1007/s11010-025-05245-8.

The Role of Intravesicular Proteins and the Protein Corona of Extracellular Vesicles in the Development of Drug-Induced Polyneuropathy.

Yunusova N, Popova N, Udintseva I, Klyushina T, Kazantseva D, Smirnova L Curr Issues Mol Biol. 2023; 45(4):3302-3314.

PMID: 37185740 PMC: 10136474. DOI: 10.3390/cimb45040216.

Influence of Diabetes Mellitus on Oncological Outcomes for Patients Living With Cancer.

Murphy L, Sherifali D, Ali M, Ibrahim S Sci Diabetes Self Manag Care. 2023; 49(2):163-179.

PMID: 36789641 PMC: 10084523. DOI: 10.1177/26350106231153073.

Impact of diabetes (type 2) and glycemic control on health-related outcomes of patients receiving chemotherapy for non-metastatic breast cancer: a retrospective analysis.

Phillips A, Reeves D, Storey S Support Care Cancer. 2023; 31(2):114.

PMID: 36637522 DOI: 10.1007/s00520-022-07563-9.

A qualitative study of blood glucose and side effect self-management among patients with type 2 diabetes undergoing chemotherapy for cancer.

Terao N Asia Pac J Oncol Nurs. 2023; 10(2):100172.

PMID: 36632446 PMC: 9827359. DOI: 10.1016/j.apjon.2022.100172.

References

Rowinsky E, Cazenave L, Donehower R . Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst. 1990; 82(15):1247-59. DOI: 10.1093/jnci/82.15.1247. View

Lee J, Swain S . Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol. 2006; 24(10):1633-42. DOI: 10.1200/JCO.2005.04.0543. View

Fountzilas G, Kalofonos H, Dafni U, Papadimitriou C, Bafaloukos D, Papakostas P . Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol. 2004; 15(10):1517-26. DOI: 10.1093/annonc/mdh395. View

Hershman D, Weimer L, Wang A, Kranwinkel G, Brafman L, Fuentes D . Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res Treat. 2010; 125(3):767-74. DOI: 10.1007/s10549-010-1278-0. View

Eckhoff L, Knoop A, Jensen M, Ejlertsen B, Ewertz M . Risk of docetaxel-induced peripheral neuropathy among 1,725 Danish patients with early stage breast cancer. Breast Cancer Res Treat. 2013; 142(1):109-18. DOI: 10.1007/s10549-013-2728-2. View

Rivera E, Cianfrocca M . Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer. Cancer Chemother Pharmacol. 2015; 75(4):659-70. PMC: 4365177. DOI: 10.1007/s00280-014-2607-5. View

Peters C, Jimenez-Andrade J, Jonas B, Sevcik M, Koewler N, Ghilardi J . Intravenous paclitaxel administration in the rat induces a peripheral sensory neuropathy characterized by macrophage infiltration and injury to sensory neurons and their supporting cells. Exp Neurol. 2006; 203(1):42-54. DOI: 10.1016/j.expneurol.2006.07.022. View

Argyriou A, Koltzenburg M, Polychronopoulos P, Papapetropoulos S, Kalofonos H . Peripheral nerve damage associated with administration of taxanes in patients with cancer. Crit Rev Oncol Hematol. 2008; 66(3):218-28. DOI: 10.1016/j.critrevonc.2008.01.008. View

Chaudhry V, Chaudhry M, Crawford T, Simmons-OBrien E, Griffin J . Toxic neuropathy in patients with pre-existing neuropathy. Neurology. 2003; 60(2):337-40. DOI: 10.1212/01.wnl.0000043691.53710.53. View

10.

Nabholtz J, Gelmon K, Bontenbal M, Spielmann M, Catimel G, Conte P . Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol. 1996; 14(6):1858-67. DOI: 10.1200/JCO.1996.14.6.1858. View

11.

Miltenburg N, Boogerd W . Chemotherapy-induced neuropathy: A comprehensive survey. Cancer Treat Rev. 2014; 40(7):872-82. DOI: 10.1016/j.ctrv.2014.04.004. View

12.

Hamid H, Mervak C, Munch A, Robell N, Hayes J, Porzio M . Hyperglycemia- and neuropathy-induced changes in mitochondria within sensory nerves. Ann Clin Transl Neurol. 2014; 1(10):799-812. PMC: 4241807. DOI: 10.1002/acn3.119. View

13.

Pachman D, Barton D, Watson J, Loprinzi C . Chemotherapy-induced peripheral neuropathy: prevention and treatment. Clin Pharmacol Ther. 2011; 90(3):377-87. DOI: 10.1038/clpt.2011.115. View

14.

Hagiwara H, Sunada Y . Mechanism of taxane neurotoxicity. Breast Cancer. 2004; 11(1):82-5. DOI: 10.1007/BF02968008. View

15.

Aslam A, Singh J, Rajbhandari S . Pathogenesis of painful diabetic neuropathy. Pain Res Treat. 2014; 2014:412041. PMC: 4026988. DOI: 10.1155/2014/412041. View

16.

Argyriou A, Polychronopoulos P, Koutras A, Xiros N, Petsas T, Argyriou K . Clinical and electrophysiological features of peripheral neuropathy induced by administration of cisplatin plus paclitaxel-based chemotherapy. Eur J Cancer Care (Engl). 2007; 16(3):231-7. DOI: 10.1111/j.1365-2354.2006.00718.x. View

17.

Schneider B, Zhao F, Wang M, Stearns V, Martino S, Jones V . Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer. J Clin Oncol. 2012; 30(25):3051-7. PMC: 3732004. DOI: 10.1200/JCO.2011.39.8446. View

18.

Verstappen C, Heimans J, Hoekman K, Postma T . Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs. 2003; 63(15):1549-63. DOI: 10.2165/00003495-200363150-00003. View

19.

Partanen J, Niskanen L, Lehtinen J, Mervaala E, Siitonen O, Uusitupa M . Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 1995; 333(2):89-94. DOI: 10.1056/NEJM199507133330203. View

20.

Hausheer F, Schilsky R, Bain S, Berghorn E, Lieberman F . Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol. 2006; 33(1):15-49. DOI: 10.1053/j.seminoncol.2005.12.010. View